India Corporate Governance MCA ROC Filings — April 11, 2026
Across 50 MCA Corporate Governance filings dated April 11, 2026, the dominant theme is routine board governance compliance including 15+ director appointments/re-appointments via postal ballots/EGMs (e.g., Supriya Lifescience 99.86% approval), 10+ upcoming board meetings for audited FY26 results (e.g., Garden Reach April 27), and trading window closures signaling Q4 earnings season. Positive capital allocation trends include promoter stake hikes via warrant conversions (Kiri Industries +4.99% to 41.71%, Mardia Samyoung +11.54% dilution to non-promoters but positive sentiment) and fundraising approvals (Vikas Lifecare ₹200 Cr warrants, MBL Infra ₹300 Cr). Few financial disclosures show mixed trends: Uravi Defence 9M revenue +45% YoY to ₹2,577 L but operational profit -55% YoY to ₹66 L; Swadha Nature FY26 net loss widened to ₹13 L (+394% YoY) with revenue -90% YoY. Risks cluster around isolated resignations (Sri Adhikari ID resignation amid going concern note) and rights issues at par (Panafic, Automobile Products signaling distress). No widespread director disqualifications; focus shifts to EGM catalysts (RBL Bank May 4 for foreign investor rights). Overall, stable governance supports portfolio monitoring for earnings catalysts, with bullish signals from promoter confidence in midcaps.